Corbion Valuation
Is CRBN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of CRBN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: CRBN (€19.56) wird über unserer Schätzung des Fair Value (€18.75) gehandelt.
Deutlich unter dem Marktwert: CRBN über unserer Schätzung des beizulegenden Zeitwerts gehandelt wird.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CRBN?
Other financial metrics that can be useful for relative valuation.
| What is CRBN's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | €1.17b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | 10.8x |
| PEG Ratio | 1.2x |
Price to Earnings Ratio vs Peers
How does CRBN's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.9x | ||
AKZA Akzo Nobel | 26.2x | 15.5% | €11.7b |
AMG AMG Critical Materials | 7.4x | 15.6% | €691.8m |
APAM Aperam | 10.3x | 21.9% | €2.1b |
HYDRA Hydratec Industries | 11.7x | n/a | €184.2m |
CRBN Corbion | 16.1x | 13.3% | €1.2b |
Price-To-Earnings gegen Gleichaltrige: CRBN ist auf der Grundlage des Price-To-Earnings Verhältnisses (16.9x) im Vergleich zum Durchschnitt der Vergleichsgruppe (13.1x) teuer.
Price to Earnings Ratio vs Industry
How does CRBN's PE Ratio compare vs other companies in the European Chemicals Industry?
Price-To-Earnings gegen Industrie: CRBN ist aufgrund seines Price-To-Earnings Verhältnisses (15.9x) im Vergleich zum European Chemicals Branchendurchschnitt (17.2x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is CRBN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 16.1x |
| Fair PE Ratio | 11.3x |
PM vs. Fair Ratio: CRBN ist teuer auf der Grundlage des Verhältnisses Price-To-Earnings (16.9x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (9.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €19.87 | €23.48 +18.2% | 22.5% | €29.00 | €13.40 | n/a | 6 |
| Mar ’25 | €19.56 | €22.75 +16.3% | 24.5% | €29.00 | €13.40 | n/a | 6 |
| Feb ’25 | €17.20 | €22.75 +32.3% | 24.5% | €29.00 | €13.40 | n/a | 6 |
| Jan ’25 | €19.38 | €24.42 +26.0% | 14.9% | €29.00 | €18.50 | n/a | 6 |
| Dec ’24 | €16.62 | €24.42 +46.9% | 14.9% | €29.00 | €18.50 | n/a | 6 |
| Nov ’24 | €16.14 | €24.42 +51.3% | 14.9% | €29.00 | €18.50 | n/a | 6 |
| Oct ’24 | €18.86 | €29.58 +56.9% | 16.4% | €37.00 | €23.00 | n/a | 6 |
| Sep ’24 | €21.84 | €29.58 +35.5% | 16.4% | €37.00 | €23.00 | n/a | 6 |
| Aug ’24 | €21.50 | €29.13 +35.5% | 16.1% | €36.00 | €23.00 | n/a | 4 |
| Jul ’24 | €21.86 | €29.13 +33.2% | 16.1% | €36.00 | €23.00 | n/a | 4 |
| Jun ’24 | €25.42 | €35.40 +39.3% | 9.1% | €38.11 | €30.00 | n/a | 4 |
| May ’24 | €28.50 | €35.40 +24.2% | 9.1% | €38.11 | €30.00 | n/a | 4 |
| Apr ’24 | €30.24 | €36.65 +21.2% | 10.7% | €40.00 | €30.00 | €19.85 | 4 |
| Mar ’24 | €35.68 | €38.28 +7.3% | 10.5% | €43.00 | €32.00 | €19.56 | 4 |
| Feb ’24 | €35.44 | €38.28 +8.0% | 10.5% | €43.00 | €32.00 | €17.20 | 4 |
| Jan ’24 | €31.84 | €33.03 +3.7% | 12.4% | €38.11 | €27.00 | €19.38 | 4 |
| Dec ’23 | €33.10 | €33.03 -0.2% | 12.4% | €38.11 | €27.00 | €16.62 | 4 |
| Nov ’23 | €26.74 | €36.22 +35.5% | 20.3% | €49.00 | €27.00 | €16.14 | 5 |
| Oct ’23 | €25.66 | €38.22 +49.0% | 15.1% | €49.00 | €32.00 | €18.86 | 5 |
| Sep ’23 | €28.18 | €40.02 +42.0% | 11.7% | €49.00 | €36.00 | €21.84 | 5 |
| Aug ’23 | €33.96 | €40.32 +18.7% | 11.2% | €49.00 | €36.00 | €21.50 | 5 |
| Jul ’23 | €28.78 | €40.82 +41.8% | 11.5% | €49.00 | €36.00 | €21.86 | 5 |
| Jun ’23 | €33.42 | €40.82 +22.1% | 11.5% | €49.00 | €36.00 | €25.42 | 5 |
| May ’23 | €33.06 | €40.82 +23.5% | 11.5% | €49.00 | €36.00 | €28.50 | 5 |
| Apr ’23 | €31.14 | €41.22 +32.4% | 11.0% | €49.00 | €36.00 | €30.24 | 5 |
Analysten-Prognose: Das Kursziel liegt weniger als 20% über dem aktuellen Aktienkurs.